Academic education
| 1979 - 1985 | Study of medicine, Leipzig University, Medical School of Erfurt |
Academic degree
| 1997 | Habilitation in Internal Medicine, University of Heidelberg |
| 1988 | Dr. med., Medical School of Erfurt |
| 1985 | Diploma in Medicine, Medical School of Erfurt |
Professional career
| 2010 - 2020 | Vice Dean for Research, Medical Faculty, Friedrich-Schiller-University Jena |
| since 2010 | Director, UniversityTumorCenter Jena |
| since 2010 |
Director, Department of Hematology and Oncology, Jena University Hospital, Jena |
| 2007 - 2009 |
Full (W3) Professor, Head of the Department of Leukemia Research, Medical Faculty Mannheim, |
| 2003 - 2007 | Associate Professor, University of Heidelberg |
| 1997 - 2003 | Senior lecturer and consultant, 3rd Department of Internal Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany |
| 1994 - 1995 | Research fellow, LRF Leukaemia Unit, Hammersmith Hospital, Royal Postgraduate Medical School, London, U.K. |
| 1990 - 1994 | Senior registrar at the 3rd Department of Internal Medicine, |
| & 1995 - 1997 | Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany |
| 1985-1989 | Registrar and senior registrar at the outpatients department of internal medicine, Medical School of Erfurt, Germany |
Editorships, scientific committees, chairs
| 2019-2023 | Mitglied des Beirates der Deutschen Krebshilfe e.V. und Vorsitzender des Fachausschusses Klinische Studien der Deutschen Krebshilfe e.V. |
| seit 2018 | Sächsische Akademie der Wissenschaften zu Leipzig |
| seit 2014 | Editor-in-Chief, Leukemia |
| seit 2010 | Mitglied der Editorial Boards: Die Onkologie, Ann Hematol, Bone Marrow, Transplantation, Blood Cancer Journal, J Cancer Res Clin Oncol |
| seit 2014 | Akademie gemeinnütziger Wissenschaften zu Erfurt |
| 2014-2024 | Mitglied des Kuratoriums, Leibniz-Institut für Alternsforschung, Jena |
| seit 2009 | Thüringische Krebsgesellschaft (Vorsitzender seit 2011) |
| seit 2003 | Mitantragsteller und Mitglied des Steering Boards, European LeukemiaNet, Network of Excellence im 6. Rahmenprogramm der EU |
| seit 2002 | Arbeitsgemeinschaft Internistische Onkologie (AIO, Vorstandsmitglied 2007-2013) |
| seit 2001 | Deutsche Krebsgesellschaft (DKG, Vorstandsmitglied 2012-2021, Kongresspräsident 2020) |
| seit 1999 | Mitglied des Vorstandes, Kompetenznetz „Akute und chronische Leukämien“ |
| seit 1990 | Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) (Beiratsmitglied 2003-2012, Kongresspräsident 2016, Vorsitzender 2022-2025) |
Research fields
Publications
688 peer reviewed publication, H index 116, listed in „Highly Cited Researchers“ 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023 (Clarivate Analytics).
ORCID-ID 0000-0003-0626-0834
10 most important publications
- Chan LN, Chen Z, Braas D, Lee J, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sanchez-Garcia I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. (2017) Metabolic gatekeeper function of B-lymphoid transcription factors. Nature, in press
- Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O’Brien SG, Druker BJ, for the IRIS Investigators. (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 376:917-27.
- Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. (2016) Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 34:2333-40.
- Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. (2016) PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 22:379-87
- Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30:1044-54.
- Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A. (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 32:415-23
- Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 362:2260-70
- Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. (2009) Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. J Clin Oncol 27:4204-10
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STI571 CML Study Group. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:645-52
- Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R, Gambacorti- Passerini C, Corneo G, D'Incalci M. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163